In the United States between 2005 and 2014, inpatient prevalence of HAV in kidney transplant recipients was 23.42 cases per 100,000 admissions, and hospitalization for HAV after kidney transplantation was associated with ICU stay.
Treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) appears to be associated with an early high incidence of hepatocellular carcinoma (HCC) in patients with undefined or nonmalignant nodules.
Glecaprevir/pibrentasvir therapy is effective and well tolerated in patients aged > 75 years with hepatitis C virus (HCV) infection.
Hepatitis B surface antigen loss after nucleos(t)ide analogue or peginterferon (Peg-IFN)-containing regimens is durable in most patients with chronic hepatitis B.
Front-line providers minimally could check HBV DNA and ALT during pregnancy to assess mother‐to‐child transmission risk but HBeAg is recommended to be included in the initial HBV evaluation to get a more comprehensive understanding of the patient’s HBV disease state.
Viral hepatitis causing concomitant acute pancreatitis is a rare entity and outcomes vary depending on the type of hepatitis virus.
Because after hepatitis B viral suppression the cause and intervention for elevated alanine aminotransferase is somewhat unknown, investigators conducted a real-world study.
Lenvervimab was well tolerated and reduced levels of HBsAg to below undetectable levels for up to 1 month in patients with chronic HBV infection.
Patients with HCV infection should receive DAA therapy even if they have alcohol use disorder, diabetes, cirrhosis, or hepatic encephalopathy.
HBsAg, interferon inducible protein-10, and hepatitis B core related antigen serum levels can be useful for the decisions and management of treatment discontinuation in non-cirrhotic white patients with HBeAg-negative chronic hepatitis B.
